Skip to content
DataLookout
Menu

NCT07925554

Interferon-α Maintenance in Favorable-Risk AML

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

2-Year Cumulative Incidence of Relapse
Timeframe: 2 years after enrollment

Secondary (4)

2-Year Event-Free Survival (EFS)
2-Year Overall Survival (OS)
MRD Conversion Rate Among Patients With MRD-Positive Disease at Enrollment
Number of Participants With Grade 3 or Higher Adverse Events

Arms and interventions

Peginterferon Alfa-2b Maintenance TherapyExperimental

Eligible patients with favorable-risk acute myeloid leukemia (AML) in first complete remission (CR1) after consolidation chemotherapy will receive peginterferon alfa-2b injection at a dose of 135 μg once weekly by subcutaneous injection for 6 months. Participants will be monitored for disease relapse, measurable residual disease (MRD), survival, and treatment-related adverse events, with follow-up for 2 years after enrollment.

Biologicals: pegylated interferon alfa-2b

Sites

1 site in 1 country

  • Peking University People's HospitalBeijing, China